Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.58 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.58 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983867 | 0.96 | FOLH1 (0.65) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL30892473 | 0.96 | FOLH1 (0.65) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL23796954 | 0.90 | ALDH1A1 (0.66) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL7273836 | 0.90 | FOLH1 (0.61) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL26158608 | 0.89 | FOLH1 (0.57) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL23809720 | 0.89 | FOLH1 (0.57) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL26158612 | 0.89 | FOLH1 (0.57) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL16416469 | 0.88 | TSHR (0.61) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL344833 | 0.88 | FOLH1 (0.68) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 | |
| SCHEMBL383569 | 0.88 | FOLH1 (0.60) | FOLH1ALDH1A1KDM4EPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154143-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| CN-115279730-B | 2, 5-Or 2, 6-disubstituted hydroquinone derivatives having at least one carboxyl, sulfo or amido group, useful as medicaments | OM药物公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4118069-B1 | PARA-HYDROQUINONE DERIVATIVES AS VEGF, TNF AND/OR IL INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES | OM PHARMA SA (CH) | 2024-10-23 | — | — | EP | disclosed |
| EP-4387619-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL Business Ltd (GB) | 2024-06-26 | — | — | EP | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230118142-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2023-04-20 | — | — | US | disclosed |
| US-20230101069-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 | UCL BUSINESS LTD (GB) | 2023-03-30 | — | — | US | disclosed |
| WO-2023021149-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2023-02-23 | — | — | WO | disclosed |
| EP-4118069-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-9102609-B2 | Functionalization of organic molecules using metal-organic frameworks (MOFS) as catalysts | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-11 | — | — | US | disclosed |
| US-8916722-B2 | Complex mixed ligand open framework materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916722-B2 | Complex mixed ligand open framework materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916722-B2 | Complex mixed ligand open framework materials | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140012039-A1 | FUNCTIONALIZATION OF ORGANIC MOLECULES USING METAL-ORGANIC FRAMEWORKS (MOFS) AS CATALYSTS | BASF SE (DE) | 2014-01-09 | — | — | US | disclosed |
| US-20140012039-A1 | FUNCTIONALIZATION OF ORGANIC MOLECULES USING METAL-ORGANIC FRAMEWORKS (MOFS) AS CATALYSTS | BASF SE (DE) | 2014-01-09 | — | — | US | disclosed |
| US-20120259135-A1 | COMPLEX MIXED LIGAND OPEN FRAMEWORK MATERIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259135-A1 | COMPLEX MIXED LIGAND OPEN FRAMEWORK MATERIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120259135-A1 | COMPLEX MIXED LIGAND OPEN FRAMEWORK MATERIALS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012012495-A2 | FUNCTIONALIZATION OF ORGANIC MOLECULES USING METAL-ORGANIC FRAMEWORKS (MOFS) AS CATALYSTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140012039-A1 | FUNCTIONALIZATION OF ORGANIC MOLECULES USING METAL-ORGANIC FRAMEWORKS (MOFS) AS CATALYSTS | POF1B, EPCAM, MGMT | FOLH1 399/4885ALDH1A1 1496/4885KDM4E 1502/4885 |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | FOLH1 1436/4885ALDH1A1 3025/4885KDM4E 3269/4885 |
| US-20230101069-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 | PYGL, FGB, MMP8 | FOLH1 300/4885ALDH1A1 705/4885KDM4E 4333/4885 |
| US-20230118142-A1 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | LPO, AOX1, MPO | FOLH1 631/4885ALDH1A1 328/4885KDM4E 3809/4885 |
| US-20250154143-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | CYP2B6, CBR3, CYP2A6 | FOLH1 1236/4885ALDH1A1 1417/4885KDM4E 4634/4885 |
| US-20120259135-A1 | COMPLEX MIXED LIGAND OPEN FRAMEWORK MATERIALS | NECTIN4, PICALM, MICA | FOLH1 2158/4885ALDH1A1 4707/4885KDM4E 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.